Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-Term Safety and Tolerability of Peginterferon Beta-1a: Interim Analysis From ATTAIN, a Phase 3 Extension Study
Multiple Sclerosis
(-)
002
Authors/Disclosures
Marcelo C. Kremenchutzky, MD, FÂ鶹´«Ã½Ó³»­ (Lhsc - UWO)
PRESENTER 		No disclosure on file
Shifang Liu No disclosure on file
No disclosure on file
Serena W. Hung, MD Dr. Hung has received personal compensation for serving as an employee of Atalanta Therapeutics. Dr. Hung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LoQus23 . Dr. Hung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AS2 Bio. Dr. Hung has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Ataxia Foundation. Dr. Hung has or had stock in Atalanta Therapeutics.
Ali Seddighzadeh No disclosure on file
Vladimir Evilevitch No disclosure on file
Frederik Barkhof, MD, PhD (Image Analysis Center) Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Frederik Barkhof has received personal compensation in the range of $0-$499 for serving as a Consultant for Biogen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Combinostics. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IXICO. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Frederik Barkhof has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI.